Biologics Contract Manufacturing

In Collaboration, Our Cutting-edge Is Your Tool

As your global partners in contract manufacturing of world-class biologics, Dr. Reddy’s Biologics legacy, and mastery gives you the toolbox you need to chisel out your path ahead.

Mammalian and Bacterial

cell culture capabilities; stainless steel and single-use biotechnology reactors

Vials, Pre-filled Syringes (PFS) and Auto Injector Assembly

versatile filling and assembling capabilities

Premium Inputs and State-of-the-art Equipment

Ensuring highest quality in Biologics contract manufacturing

Our Manufacturing Capabilities and Capacity

Excellence in Manufacturing

Dr. Reddy's manufacturing facilities are equipped with mammalian and bacterial cell culture units, including advanced stainless steel bioreactors and India’s first single-use biotechnology platform, reducing cross-contamination risks. The facilities include cutting-edge fill finish capabilities for vials and pre-filled syringes (PFS), supported by high-precision filling lines, visual inspection systems, and fully automated packaging. With a capacity to produce 12 million vials and 18 million PFS annually, backed by a $200 million investment and 350+ technical staff, Dr. Reddy’s meets global quality standards with accreditations from regulatory bodies across the Europe, Latin America and multiple international markets.

Built for Capacity

Dr. Reddy's Biologics combines scale, flexibility, and advanced technologies to meet diverse Biologics manufacturing needs. What’s on the table? As a Biosimilars Contract Manufacturing Organisation, we are well equipped with world-class manufacturing capabilities. A quick look below.

Clinical and Commercial Manufacturing

We specialise in both Drug Substance manufacturing (DS) and Drug Product manufacturing (DP) at clinical and commercial scales. DS production is available at 200L and 1,000L scales, utilising both stainless steel and single-use technologies. Our integrated fill finish capabilities package products into vials and prefilled syringes (PFS).

Quick Figures

regulatory audits under belt
technical operators
manufacturing capacity
of research and development laboratory

We Meet Global Standards

CDSCO
ISO 9001
INVIMA
SAHPRA

Collaboration is the Key

Explore opportunities for collaboration that serve our mutual passions for robust healthcare access and critical therapies for all.

Our News, Stories, and Insights

Randomized, Double-Blind
  • Publication
  • 06-12-2019

Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma

  • Publication
  • 04-11-2022

Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamics evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

  • Publication
  • 31-12-2017

Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL), at Chicago, IL,

  • Publication
  • 02-12-2016

Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (Mabthera) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma.

Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.

 

Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.